{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:32:59Z","timestamp":1772613179494,"version":"3.50.1"},"reference-count":28,"publisher":"American Diabetes Association","issue":"2","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,2,1]]},"abstract":"<jats:p>OBJECTIVE\u2014To assess the effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes treated with intensive insulin regimens.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014Intensively treated (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII] pump therapy) patients with type 1 diabetes completed a study-specific treatment satisfaction questionnaire following 29 weeks of either placebo (n = 136) or pramlintide (n = 130) treatment in a double-blind, noninferiority pramlintide dose titration trial. End points included patient reported outcomes, their relationship to insulin treatment regimen, A1C, weight, and insulin use.<\/jats:p>\n               <jats:p>RESULTS\u2014Pramlintide-treated patients reported greater treatment satisfaction in most questionnaire responses. Treatment satisfaction was similar for pramlintide-treated patients regardless of intensive insulin regimens (MDI versus CSII). Mean A1C was reduced to a similar degree in both pramlintide- (\u22120.39 \u00b1 0.07%) and placebo-treated (\u22120.45 \u00b1 0.07%) patients. However, pramlintide treatment was associated with reductions in mean body weight (\u22121.50 \u00b1 0.33 kg; P &amp;lt; 0.0001) and mealtime insulin use (\u221219.05 \u00b1 5.17%; P &amp;lt; 0.005) over 29 weeks, while placebo treatment resulted in weight gain (1.28 \u00b1 0.25 kg) and a smaller reduction in mealtime insulin use (\u22122.20 \u00b1 3.33%).<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014Despite similar reductions in A1C, pramlintide treatment resulted in greater treatment satisfaction compared with placebo treatment. This was independent of insulin delivery method.<\/jats:p>","DOI":"10.2337\/dc06-1026","type":"journal-article","created":{"date-parts":[[2007,1,26]],"date-time":"2007-01-26T20:43:19Z","timestamp":1169844199000},"page":"210-216","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":40,"title":["Effect of Adjunctive Pramlintide Treatment on Treatment Satisfaction in Patients With Type 1 Diabetes"],"prefix":"10.2337","volume":"30","author":[{"given":"David G.","family":"Marrero","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Crean","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrie","family":"Kellmeyer","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice","family":"Gloster","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Rubin","sequence":"additional","affiliation":[{"name":"Department of Medicine and Pediatrics, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Fineberg","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orville","family":"Kolterman","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"key":"2022031219035013000_R1","unstructured":"Smith JJ: NCQA\/HEDIS guidelines for diabetes. Manag Care\u200810(Suppl. 2): 3\u20135, 2001"},{"key":"2022031219035013000_R2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care\u200828(Suppl. 1): S4\u2013S36, 2005","DOI":"10.2337\/diacare.28.suppl_1.S4"},{"key":"2022031219035013000_R3","doi-asserted-by":"crossref","unstructured":"The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med\u2008329: 977\u2013986, 1993","DOI":"10.1056\/NEJM199309303291401"},{"key":"2022031219035013000_R4","doi-asserted-by":"crossref","unstructured":"DCCT\/EDIC Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med\u2008342: 381\u2013389, 2000","DOI":"10.1056\/NEJM200002103420603"},{"key":"2022031219035013000_R5","doi-asserted-by":"crossref","unstructured":"The Diabetes Control and Complications Trial Research Group: Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care\u200811: 567\u2013573, 1988","DOI":"10.2337\/diacare.11.7.567"},{"key":"2022031219035013000_R6","doi-asserted-by":"crossref","unstructured":"Cryer PE: Banting Lecture: Hypoglycemia: the limiting factor in the management of IDDM. Diabetes\u200843: 1378\u20131389, 1994","DOI":"10.2337\/diabetes.43.11.1378"},{"key":"2022031219035013000_R7","doi-asserted-by":"crossref","unstructured":"Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV: Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care\u200824: 1858\u20131862, 2001","DOI":"10.2337\/diacare.24.11.1858"},{"key":"2022031219035013000_R8","doi-asserted-by":"crossref","unstructured":"Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR: Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care\u200826: 1\u20138, 2003","DOI":"10.2337\/diacare.26.1.1"},{"key":"2022031219035013000_R9","doi-asserted-by":"crossref","unstructured":"Derr R, Garrett E, Stacy GA, Saudek CD: Is HbA1c affected by glycemic instability? Diabetes Care\u200826: 2728\u20132733, 2003","DOI":"10.2337\/diacare.26.10.2728"},{"key":"2022031219035013000_R10","doi-asserted-by":"crossref","unstructured":"Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE: Psychosocial problems and barriers to improved diabetes management: results of the cross-national diabetes attitudes, wishes and needs (DAWN study). Diabet Med\u200822: 1379\u20131385, 2005","DOI":"10.1111\/j.1464-5491.2005.01644.x"},{"key":"2022031219035013000_R11","doi-asserted-by":"crossref","unstructured":"Young A: Amylin\u2019s physiology and its role in diabetes. Curr Opin Endocrinol Dia\u20084: 282\u2013290, 1997","DOI":"10.1097\/00060793-199708000-00006"},{"key":"2022031219035013000_R12","doi-asserted-by":"crossref","unstructured":"Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG: Amylin concentrations and glucose control. Lancet\u2008339: 1179\u20131180, 1992","DOI":"10.1016\/0140-6736(92)90785-2"},{"key":"2022031219035013000_R13","doi-asserted-by":"crossref","unstructured":"Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG: Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care\u200826: 3074\u20133079, 2003","DOI":"10.2337\/diacare.26.11.3074"},{"key":"2022031219035013000_R14","doi-asserted-by":"crossref","unstructured":"Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, James A: Ruggles JA, Kolterman OG, Weyer C: Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev\u200820: 55\u201360, 2004","DOI":"10.1002\/dmrr.419"},{"key":"2022031219035013000_R15","doi-asserted-by":"crossref","unstructured":"Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Strobel S, Wang Y Burns C, Lush C, Weyer C, Horowitz M: Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia\u200848: 838\u2013848, 2005","DOI":"10.1007\/s00125-005-1732-4"},{"key":"2022031219035013000_R16","doi-asserted-by":"crossref","unstructured":"Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG: A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care\u200825: 724\u2013730, 2002","DOI":"10.2337\/diacare.25.4.724"},{"key":"2022031219035013000_R17","doi-asserted-by":"crossref","unstructured":"Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG: Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated patients with type 2 diabetes. Diabetes Technol Ther\u20084: 51\u201361, 2002","DOI":"10.1089\/15209150252924094"},{"key":"2022031219035013000_R18","doi-asserted-by":"crossref","unstructured":"Edelman S, Garg S, Frias J, Maggs D, Wang Y, Strobel S, Lutz K, Kolterman OG: A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care\u200829: 2189\u20132195, 2006","DOI":"10.2337\/dc06-0042"},{"key":"2022031219035013000_R19","unstructured":"Bradley C: Diabetes treatment satisfaction questionnaire (DTSQ). In Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Management. Bradley C, Ed. London, Harwood Academic Publishers, 1994, p. 111\u2013132"},{"key":"2022031219035013000_R20","doi-asserted-by":"crossref","unstructured":"Bott U, Mu\u0308hlhauser I, Overmann H, Berger M: Validation of a diabetes-specific quality of life scale for patients with type 1 diabetes. Diabetes Care\u200821: 757\u2013769, 1998","DOI":"10.2337\/diacare.21.5.757"},{"key":"2022031219035013000_R21","doi-asserted-by":"crossref","unstructured":"Jacobs MA, Keulen ET, Kanc K, Casteleijn S, Scheffer P, Deville W, Heine RJ: Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients: a comparison with human regular insulin during a three-meal test period. Diabetes Care\u200820: 1279\u20131286, 1997","DOI":"10.2337\/diacare.20.8.1279"},{"key":"2022031219035013000_R22","doi-asserted-by":"crossref","unstructured":"Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW: The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes\u200854: 1100\u20131107, 2005","DOI":"10.2337\/diabetes.54.4.1100"},{"key":"2022031219035013000_R23","doi-asserted-by":"crossref","unstructured":"Bott U, Ebrahim S, Hirschberger S, Skovlund SE: Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med\u200820: 626\u2013634, 2003","DOI":"10.1046\/j.1464-5491.2003.01010.x"},{"key":"2022031219035013000_R24","doi-asserted-by":"crossref","unstructured":"Kotsanos JG, Vignati L, Huster W, Andrejasich C, Boggs MB, Jacobson AM, Marrero D, Mathias SD, Patrick D, Zalani S, Anderson J: Health-related quality-of-life results from multinational clinical trials of Lispro. Diabetes Care\u200820: 948\u2013958, 1997","DOI":"10.2337\/diacare.20.6.948"},{"key":"2022031219035013000_R25","doi-asserted-by":"crossref","unstructured":"DAFNE Study Group: Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomized controlled trial. Br J Med\u2008325: 1\u20136, 2002","DOI":"10.1136\/bmj.325.7367.746"},{"key":"2022031219035013000_R26","doi-asserted-by":"crossref","unstructured":"Cox DJ, Kovatchev BP, Gonder-Frederick LA, Summers KH, McCall A, Grimm KJ, Clarke WL: Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care\u200828: 71\u201377, 2005","DOI":"10.2337\/diacare.28.1.71"},{"key":"2022031219035013000_R27","unstructured":"Kovatchev BP, Cox DJ, Summers KH, Gonder-Frederick LA, Clarke WL: Postprandial glucose dynamics and associated symptoms in type 2 diabetes mellitus. J Appl Res\u20083: 449\u2013458, 2003"},{"key":"2022031219035013000_R28","doi-asserted-by":"crossref","unstructured":"Sommerfield AJ, Deary IJ, Frier BM: Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes. Diabetes Care\u200827: 2335\u20132340, 2004","DOI":"10.2337\/diacare.27.10.2335"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/30\/2\/210\/595409\/zdc00207000210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/30\/2\/210\/595409\/zdc00207000210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T20:21:05Z","timestamp":1647116465000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/30\/2\/210\/28391\/Effect-of-Adjunctive-Pramlintide-Treatment-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc06-1026","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,1]]}}}